Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in people with type 2 diabetes: The DELIVER-G study.

Bailey, Timothy S; Gill, Jasvinder; Jones S, Merwyn; Shenoy, Laxmi; Nicholls, Charlie; Westerbacka, Jukka

Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in people with type 2 diabetes: The DELIVER-G study.

Bailey, Timothy S; Gill, Jasvinder; Jones S, Merwyn; Shenoy, Laxmi; Nicholls, Charlie; Westerbacka, Jukka.

Affiliation

Bailey TS; AMCR Institute, Escondido, California, USA.
Gill J; Sanofi, Bridgewater, New Jersey, USA.
Jones S M; Accenture, Bangalore, India.
Shenoy L; Accenture, Bangalore, India.
Nicholls C; Sanofi, Reading, UK.
Westerbacka J; Sanofi, Paris, France.

Diabetes Obes Metab ; 24(8): 1617-1622, 2022 08.

Article in En | MEDLINE | ID: mdl-35491520

Subject(s)

Diabetes Mellitus, Type 2; Hypoglycemia; Diabetes Mellitus, Type 2/drug therapy; Glucagon-Like Peptide 1/therapeutic use; Glucagon-Like Peptide-1 Receptor/therapeutic use; Glycated Hemoglobin/analysis; Humans; Hypoglycemia/chemically induced; Hypoglycemia/epidemiology; Hypoglycemia/prevention & control; Hypoglycemic Agents/adverse effects; Insulin/therapeutic use; Insulin Glargine/adverse effects; Middle Aged

Key words

basal insulins; insulin analogues; insulin treatment; real-world outcomes; type 2 diabetes

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Hypoglycemia Limits: Humans / Middle aged Language: En Journal: Diabetes Obes Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2022 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google